Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: A multinational, 24-week, randomized, open-label, parallel-group comparison

Clinical Therapeutics

Volumn 29, Issue 11, 2007, Pages 2349-2364

  Robbins, David C ^a,d,g,h   Beisswenger, Paul J ^b,d,h   Ceriello, Antonio ^c,d,h   Goldberg, Ronald B ^d,h   Moses, Robert G ^d,e,h   Pagkalos, Emmanuil M ^d,f,h   Milicevic, Zvonko ^a,d,h   Jones, Cate A ^a,d,h   Sarwat, Samiha ^a,d,h   Tan, Meng H ^a,d,h  

^a ELI LILLY AND COMPANY   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e Illawarra Diabetes Service   (Australia)

^f PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^g Section of Endocrinology   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BEDTIME DOSAGE; BODY MASS; BODY WEIGHT; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT COMPLIANCE; PLASMACYTOMA; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; POSTPRANDIAL PERIOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 37449017989     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.11.016     Document Type: Article

References (44)

1. The UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354: 602]. Lancet 352 (1998) 837-853
2. Shichiri M., Kishikawa H., Ohkubo Y., and Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 Suppl 2 (2000) B21-B29
3. Stratton I., Adler A., Neil H., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
4. Nathan D., Buse J., Davidson M., et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes [published correction appears in Diabetes Care. 2006;49: 2816-2818]. Diabetes Care 29 (2006) 1963-1972
5. Yki-Jarvinen H., Kauppinen-Makelin R., Tiikkainen M., et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study. Diabetologia 49 (2006) 442-451
6. Polonsky K., Given B., and Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest. 81 (1988) 442-448
7. Herman W., Ilag L., Johnson S., et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 28 (2005) 1568-1573
8. Mooradian A., Bernbaum M., and Albert S. Narrative review: A rational approach to starting insulin therapy. Ann Intern Med. 145 (2006) 125-134
9. Monnier L., Colette C., Dunseath G., and Owens D. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30 (2007) 263-269
10. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects [WMA Web site] (2007). http://www.wma.net/e/policy/b3.htm Accessed February 17
11. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). ICH Guidelines for Good Clinical Practice (2006). http://www.ich.org/cache/compo/276-254-1.html Accessed October 25
12. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329 (1993) 977-986
13. Service F., O'Brien P., and Rizza R. Measurements of glucose control. Diabetes Care 10 (1987) 225-237
14. Chow S., and Liu J. Design and Analysis of Clinical Trials. Concepts and Methodologies (1998), Wiley, New York, NY
15. Davidson M. Starting insulin therapy in Type 2 diabetic patients. Does it really matter how? Diabetes Care 28 (2005) 494-495
16. Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
17. International Diabetes Federation. Global guideline for Type 2 diabetes (2006). http://www.idf.org/home/index.cfm?unode=B7462CCB-3A4C-472C-80E4-710074D7 4AD3 Accessed September
18. American Association of Clinical Endocrinologists. Implementation conference for ACE out patient diabetes mellitus consensus conference recommendations. Position statement (2006). http://www.aace.com/pub/pdf/guidelines/OutpatientlmplementationPositionS tatement.pdf [AACE Web site],Accessed September
19. Derr R., Garrret E., Stacy G., and Saudek C. Is HbA(lc) affected by glycaemic instability?. Diabetes Care 26 (2003) 2728-2733
20. Riddle M., Rosenstock J., Gerich J., and Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
21. Fritsche A., Schweitzer M., Haring H., and 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138 (2003) 952-959
22. Davies M., Storms F., Shutler S., et al., ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care 28 (2005) 1282-1288
23. Malone J., Kerr L., Campaigne B., et al., Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy [published correction appears in Clin Ther. 2005;27: 1112]. Clin Ther. 26 (2004) 2034-2044
24. Raskin P., Allen E., Hollander P., et al., INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 28 (2005) 260-265
25. Jacober S., Scism-Bacon J., and Zagar A. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 8 (2006) 448-455
26. Malone J., Bai S., Campaigne B., et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med. 22 (2005) 374-381
27. Kazda C., Hulstrunk H., Helsberg K., et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: A randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 20 (2006) 145-152
28. Holman R., Thorne K., Farmer A., et al., 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 357 (2007) 1716-1730
29. Ashwell S., Gebbie J., and Home P. Optimal timing of injection of once daily insulin glargine in people with type 1 diabetes using insulin lispro at meal-times. Diabet Med. 23 (2006) 46-52
30. Hamann A., Matthaei S., Rosak C., Silvestre L., and HOE901/4007 Study Group. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 26 (2003) 1738-1744
31. Janka H., Plewe G., Riddle M., et al. Comparison of basal insulin added to oral agents versus twice daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28 (2005) 254-259
32. Davies M., Storms F., Gomis R., and ATLANTUS Study Group. Insulin glargine-based therapy improves glycaemic control in patients with type 2 diabetes suboptimally con- trolled on premixed insulin therapies. Diabetes 55 Suppl 1 (2006) A108 Abstract.
33. Ward W., Beard J., Halter J., et al. Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 7 (1984) 491-502
34. Pratley R., and Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 44 (2001) 929-945
35. Bruce D., Chisholm D., Storlien L., and Kraegen E. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 37 (1988) 736-744
36. Bruttomesso D., Pianta A., Mari A., et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 48 (1999) 99-105
37. Albright E., Desmond R., and Bell D. Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 27 (2004) 632-633
38. Garg S., Gottlieb P., Hisatomi M., et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract. 66 (2004) 49-56
39. Ashwell S., Gebbie J., and Home P. Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. DiabetMed 23 (2006) 879-886
40. Chan J., Frier B., Leyk M., et al. Relationship between A1C and hypoglycemia in type 2 diabetes (T2D) patients treated with basal+prandial insulin mixture or basal insulin regimen. Diabetes 56 Suppl 1 (2007) A539 Abstract.
41. Lalli C., Ciofetta M., Del Sindaco P., et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22 (1999) 468-477
42. Nathan D., Cleary P., Backlund J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
43. Cavalot F., Petrelli A., Traversa M., et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: Lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 91 (2006) 813-819
44. Esposito K., Giugliano D., Nappo F., Marfella R., and Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110 (2004) 214-219